PMID- 32639636
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 111
IP  - 9
DP  - 2020 Sep
TI  - lncRNA IGKJ2-MALLP2 suppresses LSCC proliferation, migration, invasion, and 
      angiogenesis by sponging miR-1911-3p/p21.
PG  - 3245-3257
LID - 10.1111/cas.14559 [doi]
AB  - Because advanced laryngeal squamous cell carcinoma (LSCC) is diagnosed as a 
      malignant tumor with a poor prognosis, the associated mechanisms still need to be 
      further investigated. As key players in the development and progression of LSCC, 
      lncRNAs have attracted increasing attention from many researchers. In this study, 
      a novel lncRNA termed IGKJ2-MALLP2 was identified and investigated for its 
      effects on the development of LSCC. IGKJ2-MALLP2 expression was confirmed by 
      RT-qPCR in 78 pairs of tissues and human laryngeal carcinoma cell lines. The 
      results of this study showed that the expression of IGKJ2-MALLP2 was reduced in 
      LSCC tissues and displayed close relationships with tumor stage, lymph node 
      metastasis, and clinical stage. Using a dual-luciferase reporter assay, the 
      ability of miR-1911-3p to bind both IGKJ2-MALLP2 and p21 mRNA was demonstrated. 
      IGKJ2-MALLP2 could upregulate p21 expression by competitively binding 
      miR-1911-3p. Moreover, IGKJ2-MALLP2 effectively hindered the invasion, migration, 
      and proliferation of AMC-HN-8 and TU212 tumor cells. Furthermore, its high 
      expression could hinder the secretion of VEGF-A and suppress angiogenesis. As 
      revealed by the results of in vitro experiments, IGKJ2-MALLP2 overexpression 
      could restrict tumor growth and blood vessel formation in a xenograft model of 
      LSCC. As indicated from the mentioned findings, IGKJ2-MALLP2, which mediates p21 
      expression by targeting miR-1911-3p, was capable of regulating LSCC progression 
      and could act as an underlying therapeutic candidate to treat LSCC.
CI  - (c) 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Cao, Jing
AU  - Cao J
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
AD  - The Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical 
      University, Harbin, China.
FAU - Yang, Zhenming
AU  - Yang Z
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - An, Ran
AU  - An R
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, Heilongjiang Provincial 
      Hospital Affiliated to Harbin Institute of Technology, Harbin, China.
FAU - Zhang, Jiarui
AU  - Zhang J
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Zhao, Rui
AU  - Zhao R
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Li, Wenjing
AU  - Li W
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Xu, Licheng
AU  - Xu L
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
AD  - The Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical 
      University, Harbin, China.
FAU - Sun, Yanan
AU  - Sun Y
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Liu, Ming
AU  - Liu M
AUID- ORCID: 0000-0002-9693-2990
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Tian, Linli
AU  - Tian L
AD  - Department of Otorhinolaryngology, Head and Neck Surgery, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
LA  - eng
GR  - 81572647/National Natural Science Foundation of China/
GR  - LH 2019H014/Natural Science Foundation of Heilongjiang Province/
GR  - YJSKYCX2018-48HYD/Postgraduate Research & Practice Innovation Program of Harbin 
      Medical University/
PT  - Journal Article
DEP - 20200730
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (3' Untranslated Regions)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - 3' Untranslated Regions
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Disease Models, Animal
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics
MH  - Male
MH  - Mice
MH  - *MicroRNAs/genetics
MH  - Middle Aged
MH  - Neovascularization, Pathologic/*genetics
MH  - *RNA Interference
MH  - *RNA, Long Noncoding/genetics
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics
MH  - Vascular Endothelial Growth Factor A/genetics
MH  - Xenograft Model Antitumor Assays
PMC - PMC7469773
OTO - NOTNLM
OT  - p21
OT  - LSCC
OT  - angiogenesis
OT  - lncRNA
OT  - progression
COIS- The authors have no conflicts of interest.
EDAT- 2020/07/09 06:00
MHDA- 2020/09/15 06:00
PMCR- 2020/09/01
CRDT- 2020/07/09 06:00
PHST- 2020/03/10 00:00 [received]
PHST- 2020/06/17 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/09 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2020/07/09 06:00 [entrez]
PHST- 2020/09/01 00:00 [pmc-release]
AID - CAS14559 [pii]
AID - 10.1111/cas.14559 [doi]
PST - ppublish
SO  - Cancer Sci. 2020 Sep;111(9):3245-3257. doi: 10.1111/cas.14559. Epub 2020 Jul 30.